Clinical trials: Neurological Disease
Parkinson's Disease (PD)
Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Benserazide
The purpose of this study is to determine the effect of three single oral doses of nebicapone (50 mg, 100 mg and 200 mg) on the levodopa pharmacokinetics when administered in combination with a single-dose of controlled release…
- Trial name
- NCT02778594
- Testing
- BIA 3-202, levodopa 100 mg / benserazide 25 mg
- Where
- Portugal
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Metastases, Brain
Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer
This open label study was designed to evaluate Lapatinib effect on incidence of brain metastases in ErbB2 (HER2) positive metastatic breast cancer patients exposed to prior taxanes or anthracyclines.
- Trial name
- NCT00820222
- Testing
- capecitabine, lapatinib, trastuzumab
- Where
- 164 sites in United States, Belgium and 12 more
- Volunteers
- 540 people
- Sponsor
- Novartis Pharmaceuticals
ALS (Amyotrophic Lateral Sclerosis)
Safety and Feasibility of the EyeControl Device
The EyeControl device is an eye movement-based communication device in the form of wearable glasses with connected infrared cam-era that tracks the pupil and translates blinks and movements into commands.This study is aimed to…
- Trial name
- NCT02891629
- Testing
- EyeControl device
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Eyefree Assisting Communication Ltd
Sleep Apnea, Obstructive
HYpopnea and Apnea Detection and Treatment Performance of a New cardiOreSpiratory Holter Monitor
The HYPNOS study is an acute feasibility study to validate a new device for automatic detection and treatment of sleep apnea syndrome.
- Trial name
- HYPNOS (NCT03300037)
- Testing
- Kinesthetic stimulation
- Where
- 5 sites in France
- Volunteers
- 46 people
- Sponsor
- LivaNova
Obstructive Sleep Apnea, Excessive Sleepiness
Study Assessing Effects of JZP-110 on Driving Performance in the Treatment of Excessive Sleepiness in OSA
This trial is a randomized, double-blind, placebo-controlled, crossover study to evaluate the effect of JZP-110 on driving performance in subjects with excessive sleepiness due to obstructive sleep apnea.
- Trial name
- NCT02806895
- Testing
- JZP-110
- Where
- Netherlands
- Volunteers
- 34 people
- Sponsor
- Jazz Pharmaceuticals
Visual Impairment, Macular Edema
A Clinical Study in Current Medical Practice of the Efficacy and Safety of Ranibizumab 0.5mg in Diabetic Patients Presenting a Visual Impairment Due to Macular Edema
The purpose of this study is to evaluate the proportion of patients with a 10 letters gain on Best Corrected Visual Acuity (BCVA) at 6 months in current medical practice.
- Trial name
- LUDIC (NCT01315275)
- Testing
- Ranibizumab
- Where
- 43 sites in France
- Volunteers
- 394 people
- Sponsor
- Novartis Pharmaceuticals
Huntington's Disease
Safety Study of the Novel Drug Dimebon to Treat Patients With Huntington's Disease
This study is being conducted to determine the safety and tolerability of Dimebon in people with Huntington's disease after short-term exposure (one week) and after longer exposure (three months).
- Trial name
- NCT00387270
- Testing
- Dimebon
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Medivation, Inc.
Idiopathic Parkinson Disease
Phase 2a Study of VTX3232 in Parkinson's Disease
This is a study to understand if taking VTX3232 is safe in participants diagnosed with early stage idiopathic Parkinson's Disease (PD). Approximately 10 patients will take VTX3232 Dose A.
- Trial name
- NCT06556173
- Testing
- VTX3232
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Zomagen Biosciences Ltd.
Advanced Solid Tumors With and Without Brain Metastases
A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Advanced Solid Tumors and Metastatic Brain Cancer
This is a phase 1, multi-centre, sequential cohort, open-label, dose-escalation study of the safety, tolerability, and PK of ANG1005 in patients with solid tumors (with or without brain metastases).
- Trial name
- NCT00539383
- Testing
- ANG1005
- Where
- 3 sites in United States
- Volunteers
- 56 people
- Sponsor
- Angiochem Inc
Duchenne Muscular Dystrophy, Becker Muscular Dystrophy
Study of Ataluren (PTC124) in Nonambulatory Participants With Nonsense-Mutation-Mediated Duchenne/Becker Muscular Dystrophy (nmDMD/BMD)
Duchenne/Becker muscular dystrophy (DMD/BMD) is a genetic disorder that develops in boys. It is caused by a mutation in the gene for dystrophin, a protein that is important for maintaining normal muscle structure and function.
- Trial name
- NCT01009294
- Testing
- Ataluren, Chronic Corticosteroid Therapy
- Where
- 6 sites in United States, United Kingdom
- Volunteers
- 6 people
- Sponsor
- PTC Therapeutics
Frontotemporal Dementia
An Open-Label, Expanded Access Protocol of LAM-002A in C9ORF72-Associated Frontotemporal Dementia (FTD)
This is an open-label, single subject, expanded access protocol (EAP) of the LAM-002A investigational product administered orally at 125 mg BID for 52 weeks.
- Trial name
- NCT05483322
- Testing
- LAM-002A
- Sponsor
- IRulya Therapeutics Inc.
Stroke, Sleep Apnea
Impact of Early Ventilation in Stroke Outcomes in Patients With Sleep Apnea After First Ever Stroke
To evaluate the impact of early ventilation in stroke outcomes in patients with sleep apnea and first ever stroke, 1 month after stroke.
- Trial name
- NCT04903951
- Testing
- Adaptive Servoventilation (ASV) therapy, Best medical treatment
- Where
- Portugal
- Volunteers
- 90 people
- Sponsor
- Philips Portuguesa S.A.
Autoimmune Encephalitis, Early-stage Panencephalitis
Monitoring of Outcomes of Cellular and Exosome-based Therapies in Autoinflammatory and Post-infectious Neuroinflammatory Syndromes
This is a prospective, non-randomized, observational registry study evaluating the clinical outcomes of patients with autoimmune or post-infectious neuroinflammatory syndromes receiving stem cell-derived biologics (including…
- Conditions
- Autoimmune Encephalitis, Early-stage Panencephalitis, Neuroinflammatory Demyelination
- Trial name
- NCT07145502
- Testing
- Allogeneic MSC infusions (IV)
- Where
- Poland
- Volunteers
- 76 people
- Sponsor
- Biocells Medical
Ornithine Transcarbamylase Deficiency
Study to Characterize Rate of Ureagenesis in Patients With Ornithine Transcarbamylase (OTC) Deficiency
The objectives of the study are to characterize urea production rates in patients with OTC, characterize the association of rate of ureagenesis and disease severity in OTC patients, characterize the association of rate of…
- Trial name
- NCT04717453
- Testing
- No Intervention
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Ultragenyx Pharmaceutical Inc
Multiple Sclerosis
BENEFIT Extension Study
To assess the long-term effects of early therapeutic intervention, i.e. within two years following a first clinical demyelinating event suggestive of MS.
- Trial name
- NCT00544037
- Testing
- Interferon beta-1b (Betaseron, BAY86-5046)
- Where
- 18 sites in Austria, Belgium and 16 more
- Volunteers
- 283 people
- Sponsor
- Bayer
PARKINSON DISEASE (Disorder), Advanced Parkinson's Disease
SAD Study in Patients With Parkinson's Disease and Motor Fluctuations
This is a randomized, placebo-controlled, single ascending dose (SAD) study of SER-252 in participants with Parkinson's Disease (PD) and motor fluctuations.
- Trial name
- NCT07422675
- Testing
- SER-252 (PEOZ-apomorphine), enFuse
- Where
- 6 sites in United States, Australia
- Volunteers
- 40 people
- Sponsor
- Serina Therapeutics
Sarcopenia in Elderly, Sarcopenia
A Study of AMC6156 in People With Sarcopenia
This clinical trial aims to find out whether AMC6156 can improve physical function and is safe in older adults with sarcopenia. Participants will take AMC6156 or a placebo daily for 12 weeks, and their movement, strength, and…
- Trial name
- NCT07072195
- Testing
- AMC6156 0.1mg, AMC6156 0.3mg, AMC6156 1.0mg
- Where
- 4 sites in South Korea
- Volunteers
- 80 people
- Sponsor
- Animuscure Inc.
Age Related Macular Degeneration
Study of WA-NG (NG-IMT) Telescope Prosthesis in Patients With End-stage Age-related Macular Degeneration
The purpose of this study is to evaluate the safety of the updated Model WA-NG telescope prosthesis (hereafter WA-NG telescope), an injectable telescope device, in patients with bilateral moderate to profound central vision…
- Trial name
- NCT04468373
- Testing
- WA-NG (NG-IMT) Telescope Prothesis
- Where
- 2 sites in Ireland, Spain
- Volunteers
- 9 people
- Sponsor
- VisionCare, Inc.
Advanced Parkinson's Disease
Levodopa-Carbidopa Intestinal Gel Open-Label Study in Advanced Parkinson's Disease
The primary objective of this study will be to provide further evidence of the long-term safety and tolerability of levodopa-carbidopa intestinal gel (Duodopa®) over 12-months in participants with advanced Parkinson's disease…
- Trial name
- NCT00335153
- Testing
- Levodopa-carbidopa intestinal gel, CADD-Legacy® 1400 ambulatory infusion pump, PEG tube
- Where
- 83 sites in United States, Australia and 14 more
- Volunteers
- 354 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Endometriosis, Pain
Endocare® (Single Care) in Pain-related Endometriosis
Endocare® treatment is a stand-alone software medical device, which is composed of a mobile application and an accessory VR headset, intended to mitigate the pain for patients prone to endometriosis.
- Trial name
- NCT04650516
- Testing
- Virtual reality, Digital control
- Where
- France
- Volunteers
- 45 people
- Sponsor
- Lucine
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.